Division of Clinical Pharmacology Archive — Page 2 of 10

July 25, 2023

Signaling pathways in liposarcomas

A broad bioinformatics approach revealed that Hedgehog signaling is upregulated in dedifferentiated liposarcoma, suggesting this pathway may be an early indicator of poor prognosis and a potential therapeutic target.

By Leigh MacMillan
June 26, 2023

Magnesium deficiency and blood pressure

Dietary magnesium depletion in a mouse model activated inflammatory pathways and molecules that promote hypertension, suggesting that increased magnesium consumption may be beneficial for reducing the prevalence of hypertension.

By Leigh MacMillan
June 8, 2023

Targeting calcium handling in A-fib

The drug ent-verticilide reduced A-fib incidence and duration in an animal model, suggesting it may be a viable therapeutic option.

By Leigh MacMillan
June 5, 2023

Vanderbilt mourns loss of renowned clinical pharmacologist Jackson Roberts II, MD

Jackson Roberts II, MD, an internationally known clinical pharmacologist in the Vanderbilt University School of Medicine who helped define the role of lipid peroxidation and oxidative stress in human disease, died May 31 in Nashville. He was 79.

By Bill Snyder
May 31, 2023

Four from VUMC receive Heart Rhythm Society awards

Four physician-scientists from Vanderbilt University Medical Center won awards during the Heart Rhythm Society’s annual meeting.

By Matt Batcheldor
Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.
March 16, 2023

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

By Leigh MacMillan